Explore the Agenda
8:00 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Honing Investment Potential in Exosome Therapeutics to Better Understand Movement in the Field & Optimise Investment in Your Company
9:00 am Understanding the Investment Landscape in Exosome Therapeutics & Evaluating the Risk Return of Clinical Validation & Scalable Platform Opportunity
- Identifying key value drivers from an investor perspective including clinical proof-ofconcept, regulatory clarity, and manufacturability at scale
- Differentiating platforms based on strength of biological rationale, delivery efficiency, and defensibility of intellectual property
- Assessing risk-adjusted return profiles across early-stage assets, focusing on translational milestones and partnering or exit opportunities
9:30 am Session Reserved for Esco Aster
10:00 am Roundtable Discussion: Understanding Investor Perspectives on Exosome Therapeutics to Navigate Risk Reward Clinical Validation & Platform Scalability in a Growing Field
- Exploring how investors assess scientific credibility, clinical maturity, and differentiation within a rapidly evolving exosome landscape
- Debating key risk factors including regulatory uncertainty, manufacturing scalability, and reproducibility of exosome-based products
- Identifying investment catalysts such as early clinical readouts, strategic partnerships, and platform validation across multiple indications
10:30 am Morning Break
Ensuring Batch to Batch Consistency in Exosome Manufacturing to Streamline Manufacturing & Overcome Variability & Scale Up Challenges
11:30 am Reviewing the Challenges & Opportunities Associated With Manufacturing of Anti-Inflammatory Exosome Products to Overcome Scale Up Challenges
- Reviewing the cost of goods consideration in EV product manufacture
- Issues to be addressed in scaling up of exosome manufacture
- Ensuring the quality and function of exosome products, including the selection and design of in vivo animal models
12:00 pm Ensuring Batch to Batch Consistency in Exosome Manufacturing to Define Critical Quality Attributes & Analytical Control Strategies
- Identifying and controlling critical quality attributes such as particle size distribution, cargo composition, and surface markers to ensure consistent product identity
- Developing robust analytical assays for release testing and in-process monitoring to detect variability early in manufacturing
- Linking manufacturing controls to functional potency to maintain reproducible biological activity across batches
12:30 pm Lunch
Analyzing The Applications of Exosomes in Inflammatory Diseases & Lethal Indications to Gain A Holistic Understanding of Their Applications
1:30 pm Exosomes Derived from Oligodendrocytes for Therapy of CNS Autoimmune Inflammatory Diseases
- Current therapies for CNS autoimmune diseases are generalized immunosuppressant. There is a clear need for antigen-specific therapies that remove auto-reactive immune cells and leave the rest of immune system intact
- Induction of antigen-specific immunological tolerance can help suppress the autoreactive immune cells without systemic immunosuppression
- Exosomes from the target cells in autoimmune diseases can be used to induce immune tolerance to only target cell antigens, and examples of this novel therapeutic approach will be presented
2:00 pm Assessing the Preclinical to Clinical Translation of XOlacta
- Analyzing loading efficiency assessment and PK/PD evaluation
- Understanding the IND process for lethal indications
- Overview of clinical assessments of XOlacta
2:30 pm Afternoon Networking Break
Exploring the Future of Exosomes & Their Use in Diagnostics to Drive Precision Medicine Applications
3:00 pm Exploring Exosomes as Next Generation Diagnostic Biomarkers to Unlock Liquid Biopsy Potential for Early Disease Detection
- Leveraging exosome cargo such as RNA, proteins, and lipids as stable, disease-specific biomarkers in accessible biofluids
- Advancing liquid biopsy approaches to enable earlier detection of cancer, neurodegeneration, and inflammatory diseases
- Improving sensitivity and specificity through enrichment and high-resolution molecular profiling techniques
3:30 pm Translating Exosome Based Diagnostics from Discovery to Clinical Use to Overcome Challenges in Standardisation & Validation
- Addressing pre-analytical and analytical variability in exosome isolation, quantification, and characterization workflows
- Establishing robust validation frameworks to ensure reproducibility and clinical reliability across patient populations
- Navigating regulatory pathways for adoption of exosome-based diagnostic assays in clinical laboratories